Nontuberculous mycobacterial pulmonary disease (NTM-PD) is increasingly recognized in the U.S. and worldwide as a debilitating disease that is challenging to diagnose and manage. Beyond the principle task of recognizing the protean imaging manifestations of NTM-PD, radiologists will need to appropriately communicate with pulmonology and infectious disease colleagues in multidisciplinary management discussions. This update on nontuberculous mycobacteria (NTM) species, their clinical significance, and imaging features aims to support these roles. Terminology mirrors that laid out by the American Thoracic Society (ATS) and Infectious Disease Society of America (IDSA) published guidelines on NTM-PD..
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1053/j.ro.2021.10.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[This corrects the article DOI: 10.1183/23120541.00791-2023.
View Article and Find Full Text PDFRecurrent NTM pulmonary disease despite avoidance of hot spring exposure in a plaque psoriasis patient treated with Secukinumab: a case report.
BMC Infect Dis
January 2025
National Clinical Research Center of Respiratory Diseases, Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, 100029, China.
Background: Recurrent Non-Tuberculous Mycobacterial Pulmonary Disease (NTM-PD) related to treatment with Secukinumab has not been previously documented.
Case Presentation: Despite adherence to treatment and avoiding hot springs, a plaque psoriasis patient experienced persistent NTM-PD relapses.
Conclusions: There is potential association between Secukinumab, an IL-17A inhibitor, and NTM disease, echoing anti-TNF biologics' NTM risk, indicating the urgent need for further research on pathogenic mechanisms and risk factors.
A two-sample mendelian randomization study of non-tuberculous mycobacteria infection and lung cancer.
J Thorac Dis
December 2024
Department of Thoracic Surgery, Affiliated Hospital of Nantong University, Nantong, China.
Background: Non-tuberculous mycobacterial lung disease may coexist or precede lung cancer, yet a causal link remains unproven. This study aimed to elucidate the causal association between non-tuberculous mycobacteria (NTM) and lung cancer.
Methods: Summary data from genome-wide association studies (GWAS) for NTM, atypical mycobacterial lung infections, and various types of lung cancer were utilized.
New Frontiers in Fighting Mycobacterial Infections: Venom-Derived Peptides.
Probiotics Antimicrob Proteins
January 2025
Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran.
Notwithstanding the indefatigable endeavors to develop effective anti-mycobacterial therapies, mycobacterial infections still present a tough problem for medicine today. The problem is further complicated by the disquieting surge of drug-resistant mycobacterial pathogens, which considerably narrows the existing therapeutic options. Thus, there is a genuine need to discover novel anti-mycobacterial drugs.
View Article and Find Full Text PDFBackground: Due to its increasing prevalence and suboptimal treatment, non-tuberculous mycobacterial (NTM) infection is an emerging problem in patients with cystic fibrosis (CF). Detailed description of regional NTM prevalence and distribution, and identification of predictors of NTM acquisition in CF are essential to optimise treatment and surveillance guidelines.
Methods: A retrospective, multi-center analysis was conducted between the years 2020 and 2022 on data from 232 adult patients registered in the Hungarian CF Registry in 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!